NVO Relative Valuation
NVO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NVO is overvalued; if below, it's undervalued.
Historical Valuation
Novo Nordisk A/S (NVO) is now in the Undervalued zone, suggesting that its current forward PE ratio of 19.55 is considered Undervalued compared with the five-year average of 28.55. The fair price of Novo Nordisk A/S (NVO) is between 107.70 to 143.75 according to relative valuation methord. Compared to the current price of 79.83 USD , Novo Nordisk A/S is Undervalued By 25.88%.
Relative Value
Fair Zone
107.70-143.75
Current Price：79.83
25.88%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
16.66
P/B
Median3y
28.82
Median5y
25.34
3.43
FCF Yield
Median3y
2.72
Median5y
3.25
Competitors Valuation Multiple
The average P/S ratio for NVO's competitors is 6.09, providing a benchmark for relative valuation. Novo Nordisk A/S Corp (NVO) exhibits a P/S ratio of 6.68, which is 9.70% above the industry average. Given its robust revenue growth of 15.63%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Novo Nordisk A/S (NVO) currently overvalued or undervalued?
What is Novo Nordisk A/S (NVO) fair value?
How does NVO's valuation metrics compare to the industry average?
What is the current P/B ratio for Novo Nordisk A/S (NVO) as of Jun 14 2025?
What is the current FCF Yield for Novo Nordisk A/S (NVO) as of Jun 14 2025?
What is the current Forward P/E ratio for Novo Nordisk A/S (NVO) as of Jun 14 2025?